Syndecan-4 drives immune escape in microsatellite-stable colorectal cancer by suppressing the formation of cytotoxic effector T cells via the PRKCA–TNFα–NF-κB axis
Results indicate that high SDC4 expression in tumors from patients with CRC is negatively correlated with CD8 + T-cell accumulation in the TME, and targeting SDC4/PRKCA may reverse immunosuppression and enhance the efficacy of immunotherapy in MSS-type CRC.